AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%
Last update at 2024-12-19T18:57:00Z
Prothena Corporation plc (PTRA): Positioning Among Top Debt-Free Stocks
Sun 18 Aug 24, 04:28 AMProthena Reports Second Quarter 2024 Financial Results and Business Highlights
Thu 08 Aug 24, 08:05 PM| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -160.48000M | -125.60500M | 71.92M | -111.42700M | -77.29800M |
| Minority interest | - | - | - | - | - |
| Net income | -147.02800M | -116.94900M | 66.97M | -111.14400M | -77.67700M |
| Selling general administrative | 61.84M | 49.90M | 46.32M | 38.70M | 35.74M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 82.96M | 53.91M | 200.58M | 0.85M | -50.02200M |
| Reconciled depreciation | 0.93M | 0.74M | 6.80M | 6.98M | 6.82M |
| Ebit | -191.03600M | -131.55700M | 71.97M | -112.73400M | -85.69700M |
| Ebitda | -190.10800M | -130.81300M | 78.78M | -105.75700M | -85.81900M |
| Depreciation and amortization | 0.93M | 0.74M | 6.80M | 6.98M | -0.12200M |
| Non operating income net other | - | - | -0.09600M | -0.06200M | 0.20M |
| Operating income | -191.03600M | -131.55700M | 71.97M | -112.73400M | -85.69700M |
| Other operating expenses | 282.41M | 185.46M | 128.60M | 113.59M | 86.57M |
| Interest expense | - | 6.70M | 6.75M | 8.28M | 8.20M |
| Tax provision | -13.45200M | -8.65600M | 4.95M | -0.28300M | 0.38M |
| Interest income | 31.01M | 6.35M | 0.04M | 1.37M | 8.20M |
| Net interest income | 31.01M | 6.35M | 0.04M | 1.37M | 8.20M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | -0.06100M |
| Other items | - | - | - | - | - |
| Income tax expense | -13.45200M | -8.65600M | 4.95M | -0.28300M | 0.38M |
| Total revenue | 91.37M | 53.91M | 200.58M | 0.85M | 0.81M |
| Total operating expenses | 282.41M | 185.46M | 128.60M | 113.59M | 86.57M |
| Cost of revenue | 8.41M | 6.74M | 82.28M | 74.88M | 50.84M |
| Total other income expense net | 30.56M | 5.95M | -0.05400M | 1.31M | 8.40M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -147.02800M | -116.94900M | 66.97M | -111.14400M | -77.67700M |
| Net income applicable to common shares | - | -116.94900M | 66.97M | -111.14400M | -77.67700M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 696.38M | 758.03M | 609.37M | 332.98M | 419.27M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 19.10M | 8.69M | 5.71M | 2.54M | 2.65M |
| Total liab | 135.02M | 135.99M | 143.32M | 148.97M | 146.35M |
| Total stockholder equity | 561.37M | 622.04M | 466.04M | 184.01M | 272.92M |
| Deferred long term liab | - | - | 102.93M | 110.24M | 110.24M |
| Other current liab | -37.01900M | 22.96M | 16.16M | 11.29M | 6.79M |
| Common stock | 0.54M | 0.52M | 0.47M | 0.40M | 0.40M |
| Capital stock | 0.54M | 0.52M | 0.47M | 0.40M | 0.40M |
| Retained earnings | -980.03100M | -833.00300M | -716.05400M | -783.02900M | -671.88500M |
| Other liab | - | 85.85M | 103.49M | 110.80M | 110.80M |
| Good will | - | - | - | - | - |
| Other assets | - | 30.93M | 10.42M | 31.14M | 13.74M |
| Cash | 620.18M | 710.41M | 579.09M | 295.38M | 375.72M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 56.89M | 50.15M | 33.45M | 25.85M | 17.71M |
| Current deferred revenue | 67.41M | 11.44M | 7.66M | 4.93M | 4.58M |
| Net debt | -608.34700M | -703.93300M | -566.76800M | -277.54200M | -352.78400M |
| Short term debt | 1.11M | 6.47M | 5.94M | 5.51M | 5.10M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 11.84M | 6.47M | 12.33M | 17.84M | 22.94M |
| Other stockholder equity | 1540.86M | 1454.52M | 1181.63M | 966.64M | 944.41M |
| Property plant equipment | - | 8.01M | 2.01M | 2.55M | 3.87M |
| Total current assets | 639.28M | 719.10M | 584.81M | 299.28M | 378.38M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 622.04M | 466.04M | 184.01M | 272.92M |
| Short term investments | - | - | - | - | - |
| Net receivables | 5.16M | 0.06M | 0.01M | 0.01M | 0.07M |
| Long term debt | - | - | - | - | - |
| Inventory | -5.15900M | -0.06200M | - | 1.35M | -0.06800M |
| Accounts payable | 25.39M | 9.27M | 3.69M | 4.12M | 1.24M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | -8.00700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.47M | 0.40M | 0.40M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -716.05400M | -783.02900M | -671.88500M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 40.24M | 12.72M | 3.35M | 1.69M | 3.79M |
| Deferred long term asset charges | - | - | - | - | 9.96M |
| Non current assets total | 57.10M | 38.94M | 24.56M | 33.69M | 40.89M |
| Capital lease obligations | 11.84M | 6.47M | 12.33M | 17.84M | 22.94M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -1.41200M | -0.46400M | -0.57500M | -0.19600M | -0.54700M |
| Change to liabilities | - | -1.99000M | -0.14400M | 7.73M | -0.53900M |
| Total cashflows from investing activities | - | -0.46400M | -0.57500M | -0.19600M | -0.54700M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 45.10M | 241.46M | 190.33M | 0.21M | 0.23M |
| Change to operating activities | - | -16.81300M | -10.27500M | -4.30200M | -4.37100M |
| Net income | -147.02800M | -116.94900M | 66.97M | -111.14400M | -77.67700M |
| Change in cash | -90.22400M | 132.17M | 282.36M | -80.34300M | -53.28800M |
| Begin period cash flow | 710.41M | 580.45M | 298.08M | 378.43M | 431.71M |
| End period cash flow | 620.18M | 712.62M | 580.45M | 298.08M | 378.43M |
| Total cash from operating activities | -133.90600M | -108.82100M | 92.61M | -80.36200M | -52.96900M |
| Issuance of capital stock | 232.78M | 223.62M | 174.79M | 78.37M | - |
| Depreciation | 0.93M | 0.74M | 6.80M | 6.98M | 6.82M |
| Other cashflows from investing activities | - | - | - | - | 0.00800M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -8.89600M | - | -10.27500M | - | - |
| Change to account receivables | -5.15900M | 0.08M | 0.01M | 0.05M | 0.05M |
| Sale purchase of stock | - | - | 93.59M | 0.21M | 0.23M |
| Other cashflows from financing activities | 45.10M | 17.84M | 190.33M | 0.21M | 0.23M |
| Change to netincome | - | 20.19M | 4.57M | -1.68800M | -1.24800M |
| Capital expenditures | 2.81M | 0.46M | 0.57M | 0.20M | 0.56M |
| Change receivables | - | - | 0.01M | 0.05M | - |
| Cash flows other operating | - | - | 20.07M | 23.18M | 24.93M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | 282.36M | -80.34300M | -53.28800M |
| Change in working capital | -20.53000M | -18.80300M | -10.40400M | 3.48M | -4.44900M |
| Stock based compensation | 40.91M | 31.32M | 24.66M | 22.01M | 23.59M |
| Other non cash items | 7.50M | 6.00M | 38.74M | 28.19M | 51.35M |
| Free cash flow | -136.71600M | -109.28500M | 92.03M | -80.55800M | -53.52400M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation plc |
4.68 39.16% | 16.63 | - | 64.10 | 13.08 | 2.13 | 6.43 | -3.0917 |
| NVO Novo Nordisk A/S |
-2.26 2.13% | 103.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.68 1.57% | 105.12 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-55.6951 12.45% | 391.80 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-4.445 0.62% | 710.17 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60
| Name | Title | Year Born |
|---|---|---|
| Dr. Gene G. Kinney Ph.D. | Pres, CEO & Director | 1969 |
| Mr. Tran B. Nguyen M.B.A. | CFO & Chief Strategy Officer | 1974 |
| Mr. Brandon S. Smith | Chief Operating Officer | 1975 |
| Ms. Carol D. Karp | Chief Regulatory Officer | 1953 |
| Dr. Hideki Garren M.D., Ph.D. | Chief Medical Officer | 1965 |
| Ms. Karin L. Walker CPA, CPA | Chief Accounting Officer & Controller | 1963 |
| Dr. Wagner M. Zago | Chief Scientific Officer | 1973 |
| Ms. Jennifer Zibuda | Director of Investor Relations & Communication | NA |
| Mr. Michael J. Malecek | Chief Legal Officer | 1966 |
| Ms. Yvonne M. Tchrakian | Company Sec. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...